Use of cops3 inhibitors for treating hepatitis b virus infection
AssigneeHoffmann-La Roche Inc.
InventorsLykke Pedersen, Souphalone Luangsay, Johanna Marie Walther, Alan James Mueller-Breckenridge
Life of this patent
Estimating the term…
Abstract
The present invention relates to a COPS3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of COPS3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to COPS3 and capable of reducing the level of a COPS3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
Claims32
A method of treating or preventing a Hepatitis B virus (HBV) infection in a subject in need thereof, the method comprising administering to the subject a therapeutically or prophylactically effective amount of a COPS3 (COPS Signalosome Subunit 3) inhibitor.
(canceled)
A nucleic acid molecule of 12 to 30 nucleotides in length comprising a contiguous nucleotide sequence of at least 12 nucleotides which is 90% complementary to a mammalian COPS3 target sequence, wherein the nucleic acid molecule is capable of inhibiting the expression of COPS3 mRNA.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.